A robust mRNA signature obtained via recursive ensemble feature selection predicts the responsiveness of omalizumab in moderate-to-severe asthma.

Publication Year: 2023

DOI:
10.1002/clt2.12306

PMCID:
PMC10655633

PMID:
38006387

Journal Information

Full Title: Clin Transl Allergy

Abbreviation: Clin Transl Allergy

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"the biological context and pathway annotation of refs and len overlapping omalizumab response-predictive genes were validated through literature research to gain a better understanding of mechanisms involved in omalizumab responsiveness2 2 1 data on individual moderate-to-severe adult asthma patients whole blood mrna profiles and clinical information was retrieved from the publicly available database 'gene expression omnibus' (geo) with accession code gse134544. data availability statement all the necessary scripts to reproduce the experiments are stored on the public github repository: https://github com/steppenwolf0/refs ."

Evidence found in paper:

"data availability statement all the necessary scripts to reproduce the experiments are stored on the public github repository: https://github com/steppenwolf0/refs ."

Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT All authors of the manuscript declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025